Sirnaomics Names Francois Lebel Clinical Development Senior VP

Sirnaomics, a biopharmaceutical company involved in discovery and development of RNAi therapeutics, appointed Francois Lebel senior vice president for preclinical and clinical development of the group. Lebel will take a leading role in the group’s late-stage product development of the innovative RNAi drug candidates.

Lebel has broad drug development experience including immunooncology and nucleic acid therapeutics. Throughout his 30-year biopharma career at companies including GSK, Pfizer, Baxter Healthcare, Medlmmune, and Chiron Corp., Lebel has designed and managed international R&D programs to successfully achieve multiple product marketing approvals.

His recent senior leadership roles include executive vice president for R&D and chief medical officer at Spectrum Pharmaceuticals, where he was responsible for preclinical and clinical development, regulatory affairs, and pharmacovigilance/drug safety, and successfully secured a novel drug marketing authorization at the U.S. FDA in 2022.

“With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarking on a journey to push its innovative drug candidates past the finish line, which requires a seasoned leader with a successful track record,” said Patrick Lu, founder, chairman of the board, executive director, President, and CEO of Sirnaomics. “With Dr. Lebel’s indepth knowledge and experience in novel drug product marketing approvals, Dr. Lebel’s addition to Sirnaomics’ senior leadership will greatly enhance our capability to advance its therapeutic candidates through the late-stage product development.

Lebel said, “I am delighted to join the Sirnaomics team at this pivotal time for STP705 with the recent positive data in skin cancer and the Group’s evolving diversified pipeline. I look forward to working closely with the U.S. FDA and investigators to efficiently generate the required data to support a marketing application.”